RxPG News Feed for RxPG News

Medical Research Health Special Topics World
  Home
 
   Health
 Aging
 Asian Health
 Events
 Fitness
 Food & Nutrition
 Happiness
 Men's Health
 Mental Health
 Occupational Health
 Parenting
 Public Health
 Sleep Hygiene
 Women's Health
  Mammography
 
   Healthcare
 Africa
 Australia
 Canada Healthcare
 China Healthcare
 India Healthcare
 New Zealand
 South Africa
 UK
 USA
 World Healthcare
 
   Latest Research
 Aging
 Alternative Medicine
 Anaethesia
 Biochemistry
 Biotechnology
 Cancer
 Cardiology
 Clinical Trials
 Cytology
 Dental
 Dermatology
 Embryology
 Endocrinology
 ENT
 Environment
 Epidemiology
 Gastroenterology
 Genetics
 Gynaecology
 Haematology
 Immunology
 Infectious Diseases
 Medicine
 Metabolism
 Microbiology
 Musculoskeletal
 Nephrology
 Neurosciences
 Obstetrics
 Ophthalmology
 Orthopedics
 Paediatrics
 Pathology
 Pharmacology
 Physiology
 Physiotherapy
 Psychiatry
 Radiology
 Rheumatology
 Sports Medicine
 Surgery
 Toxicology
 Urology
 
   Medical News
 Awards & Prizes
 Epidemics
 Launch
 Opinion
 Professionals
 
   Special Topics
 Ethics
 Euthanasia
 Evolution
 Feature
 Odd Medical News
 Climate

Last Updated: Oct 11, 2012 - 10:22:56 PM
Research Article
Women's Health Channel

subscribe to Women's Health newsletter
Health : Women's Health

   EMAIL   |   PRINT
Blood Cholesterol levels predict risk of heart disease in post menopausal women

May 24, 2008 - 11:14:50 AM , Reviewed by: Dr. Sanjukta Acharya

 
[RxPG] A new analysis of a subgroup of participants in the Women’s Health Initiative (WHI) hormone therapy clinical trials suggests that healthy, postmenopausal women whose blood cholesterol levels are normal or lower are not at increased, short-term risk for heart attack when taking hormone therapy. In particular, postmenopausal women who had no history of heart disease but whose ratio of low-density lipoprotein (LDL or “bad”) cholesterol to high-density lipoprotein (HDL, or “good”) cholesterol was less than 2.5 were at no increased risk of heart attack or death due to heart attack from taking estrogen plus progestin or estrogen alone, compared to their peers who did not take hormone therapy, after four years of follow up.

“Usefulness of Baseline Lipids and C-Reactive Protein in Women Receiving Menopausal Hormone Therapy as Predictors of Treatment-Related Coronary Events,” will be published in the June 1 issue of the American Journal of Cardiology. The study was funded by the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health.

Michael S. Lauer, M.D., director of the NHLBI Division of Prevention and Population Sciences, is available to comment on this latest analysis of the WHI hormone therapy clinical trials. He emphasizes that the primary results of the WHI hormone therapy clinical trials indicate that, overall, neither form of hormone therapy reduces the risk of heart disease in healthy, postmenopausal women, and estrogen plus progestin increases a women’s risk of heart disease. In addition, both estrogen plus progestin and estrogen alone increase the risk of stroke and blood clots – serious cardiovascular conditions that the new analysis does not address. Combination hormone therapy also increases the risk of breast cancer.

Identifying which women are more likely to be at increased risk for heart attack when taking hormone therapy can help women and their clinicians make better informed decisions about whether the benefits of hormone therapy outweigh the risks.

In general, however, women should not take hormone therapy to prevent heart disease, and women who choose to use hormone therapy for menopausal symptoms should use the lowest possible dose for the shortest duration. In addition, all women whose blood cholesterol levels are elevated are at increased risk of heart disease, regardless of whether they use hormone therapy, and they should take steps to lower their risk. Heart disease is the leading cause of death among both women and men in the United States.



Publication: American Journal of Cardiology- June 1st 2008

Funding information and declaration of competing interests: The study was funded by the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health.

Advertise in this space for $10 per month. Contact us today.


Related Women's Health News


Subscribe to Women's Health Newsletter

Enter your email address:


 About Dr. Sanjukta Acharya
This news story has been reviewed by Dr. Sanjukta Acharya before its publication on RxPG News website. Dr. Sanjukta Acharya, MBBS MRCP is the chief editor for RxPG News website. She oversees all the medical news submissions and manages the medicine section of the website. She has a special interest in diabetes and endocrinology. She can be reached for corrections and feedback at [email protected]
RxPG News is committed to promotion and implementation of Evidence Based Medical Journalism in all channels of mass media including internet.
 Additional information about the news article
Part of the National Institutes of Health, the National Heart, Lung, and Blood Institute plans, conducts, and supports research related to the causes, prevention, diagnosis, and treatment of heart, blood vessel, lung, and blood diseases; and sleep disorders. The Institute also administers national health education campaigns on women and heart disease, healthy weight for children, and other topics.
The National Institutes of Health — The Nation's Medical Research Agency — includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. It is the primary federal agency for conducting and supporting basic, clinical and translational medical research, and it investigates the causes, treatments, and cures for both common and rare diseases.
 Feedback
For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 
Contact us

RxPG Online

Nerve

 

    Full Text RSS

© All rights reserved by RxPG Medical Solutions Private Limited (India)